APOA1 anticorps (Biotin)

N° du produit ABIN6963934

Cet anticorps anti-APOA1 est un anticorps Souris Monoclonal détectant APOA1 dans WB et ELISA. Adapté pour Humain et Non-Human Primate. Ce Primary Antibody a été cité dans 5+ publications.

Aperçu rapide pour APOA1 anticorps (Biotin) (ABIN6963934)

Antigène: APOA1 (Apolipoprotein A-I (APOA1))

Reactivité: Humain, Non-Human Primate

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp APOA1 est conjugé à/à la Biotin

Application: Western Blotting (WB), ELISA

Clone: HDL 44

Détail du produit anti-APOA1 anticorps (Biotin)

Specificité: Native apolipoprotein A1 (apoA1), purified or in the form of HDL.

Réactivité croisée (Details): The monoclonal antibody cross-reacts with apoA1 from non-human primates.

Purification: Purified from in vitro cultures by protein G affinity chromatography.

Immunogène: Human HDL

Isotype: IgG1

Information d'application

Indications d'application: For quantification of apoA1 in serum/ plasma samples and cell culture supernatants using ELISA. HDL 44 is recommended as detection mAb in combination with coating mAb HDL 110 . The antibody is also suitable for immunoprecipitation and Western blot.

Commentaires:

Biotinylated through reaction with a N-hydroxysuccinimide ester of biotin.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: supplied at 1 mg/mL in PBS with 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store product at 4-8°C or frozen at -20°C or below. Avoid repeated freezing/ thawing.

Date de péremption: 18 months

Références pour anticorps anti-APOA1 (Biotin) (ABIN6963934)

Slot, Kester, Van Harten, Jongbloed, Bouwman, Teunissen, Scheltens, van der Flier, Veerhuis: "ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly." dans: Neurobiology of aging, Vol. 79, pp. 101-109, (2020) (PubMed).

Rebholz, Melchior, Welge, Remaley, Davidson, Woollett: "Effects of Multiple Freeze/Thaw Cycles on Measurements of Potential Novel Biomarkers Associated With Adverse Pregnancy Outcomes." dans: Journal of clinical and laboratory medicine, Vol. 2, Issue 1, (2017) (PubMed).

Apro, Parini, Broijersén, Angelin, Rudling: "Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients." dans: Journal of lipid research, Vol. 56, Issue 8, pp. 1633-9, (2016) (PubMed).

Bissig-Choisat, Wang, Legras, Saha, Chen, Bell, Pankowicz, Hill, Barzi, Leyton, Leung, Kruse, Himes, Goss, Wilson, Chan, Lagor, Bissig: "Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model." dans: Nature communications, Vol. 6, pp. 7339, (2015) (PubMed).

Halley, Kadakkuzha, Faghihi, Magistri, Zeier, Khorkova, Coito, Hsiao, Lawrence, Wahlestedt: "Regulation of the apolipoprotein gene cluster by a long noncoding RNA." dans: Cell reports, Vol. 6, Issue 1, pp. 222-30, (2014) (PubMed).

Détails sur APOA1

Antigène: APOA1 (Apolipoprotein A-I (APOA1))

Autre désignation: apoA1

ID gène: 335

Pathways: Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism